(function(){var loadHandler=window['sl_{EC00A760-FAC2-48CD-8603-FA3C7FB92E6B}'];loadHandler&&loadHandler(15, '<div id="spr0_36540bf"><div id="spr1_36540bf" class="kern slide"><img id="img0_36540bf" src="data/img9.png" width="1280px" height="720px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_36540bf" class="kern slide"><div id="spr3_36540bf" style="left:88px;top:38.333px;"><div style="width:0px;"><span id="txt0_36540bf" data-width="138.473969" style="left:9.6px;top:24.307px;">EMA?</span></div></div><div id="spr4_36540bf" style="left:88px;top:162.755px;"><div style="width:0px;"><span id="txt1_36540bf" class="nokern relpos" dir="auto" style="left:9.6px;top:2.861px;">•</span> <span id="txt2_36540bf" class="relpos" data-width="1037.989624" style="left:32.131px;top:-0.144px;">The European Medicines Agency (EMA) is responsible for the scientific evaluation of application for the European Union</span></div><div style="width:0px;"><span id="txt3_36540bf" data-width="829.354187" style="left:39.6px;top:22.896px;">(EU) marketing authorisations for human and veterinary medicines in the centralized procedure</span></div><div style="width:0px;"><span id="txt4_36540bf" class="nokern relpos" dir="auto" style="left:9.6px;top:97.878px;">•</span> <span id="txt5_36540bf" class="relpos" data-width="619.281250" style="left:32.131px;top:94.873px;">Under the centralized procedures, pharmaceutical companies submit a </span> <span id="txt6_36540bf" class="relpos" data-width="51.291668" style="left:32.125px;top:94.873px;">single</span> <span id="txt7_36540bf" class="relpos" data-width="338.666687" style="left:32.118px;top:94.873px;"> marketing authorization application to</span></div><div style="width:0px;"><span id="txt8_36540bf" class="relpos" data-width="179.020844" style="left:39.6px;top:118.682px;">EMA. Once granted, </span> <span id="txt9_36540bf" class="relpos" data-width="618.062500" style="left:39.593px;top:118.682px;">a centralized marketing authorization is valid in all EU Member-States</span> <span id="txt10_36540bf" class="relpos" data-width="235.677094" style="left:39.587px;top:118.682px;">, as well as in the European</span></div><div style="width:0px;"><span id="txt11_36540bf" data-width="608.500000" style="left:39.6px;top:141.722px;">Economic Area (EEA) countries (i.e. Iceland, Lichtenstein and Norway).</span></div><div style="width:0px;"><span id="txt12_36540bf" class="nokern relpos" dir="auto" style="left:9.6px;top:216.705px;">•</span> <span id="txt13_36540bf" class="relpos" data-width="1068.902954" style="left:32.131px;top:213.7px;">“Authorization decisions […] should be taken on the basis of the objective scientific criteria of quality, safety and efficacy of</span></div><div style="width:0px;"><span id="txt14_36540bf" class="relpos" data-width="356.080017" style="left:39.6px;top:237.509px;">the medicinal product concerned, to the </span> <span id="txt15_36540bf" class="relpos" data-width="425.736267" style="left:39.593px;top:237.509px;">exclusion of economic and other considerations</span> <span id="txt16_36540bf" class="relpos" style="left:39.587px;top:237.509px;">”</span></div><div style="width:0px;"><a id="hl0_36540bf" href="http://www.ema.europa.eu/" title="http://www.ema.europa.eu/" target="_blank" onclick="document.getElementById(\'coreSpr_6623461\').getCore().processTriggerEffect(this);return document.getElementById(\'coreSpr_6623461\').getCore().gotoLink(this);"><span id="txt17_36540bf" data-width="282.058594" style="left:35.133px;top:302.586px;">http://www.ema.europa.eu</span></a></div><div style="width:0px;"><span id="txt18_36540bf" data-width="980.929626" style="left:9.6px;top:338.365px;">Pricing, coverage and reimbursement have so far been national</span></div><div style="width:0px;"><span id="txt19_36540bf" data-width="215.140625" style="left:9.6px;top:379.454px;">competencies</span></div></div></div></div>', '{"s":[]}');})();